

**EPISIL® ADDED TO THE TGA REGISTER**

BTC health (ASX: BTC) announced today its wholly owned investment company BTC Speciality Health Pty Ltd has received confirmation of the inclusion to the Australian Register of Therapeutic Goods (ARTG) for its product episil®. It is anticipated that the product will be made available in Australia in the middle of this calendar year.

**episil®** is indicated for the relief of oral pain caused by inflammatory conditions of the mouth such as oral mucositis and stomatitis. Oral mucositis is a frequent and unpleasant side effect of radiation and chemotherapy.

Between 15% and 60% of cancer patients regardless of the type of cancer will experience some form of oral mucositis.

The condition causes redness, mouth sores and ulcers that can be painful, making it difficult to eat, drink and speak. Oral mucositis may lead to nutritional deficiencies or hospitalisation as a result of an inability to eat, an increased risk of infection and in some cases may result in interruption or delay of the cancer treatment.

BTC health Executive Chairman Dr. Richard Treagus commented; "We are very pleased to have received the registration of episil® only two months after we entered into a partnership with Camurus AB of Sweden. We are currently making the necessary preparations for launch and we look forward to making this novel product available to Australian patients in the coming months."

**For more information please contact:**

Dr. Richard Treagus, Executive Chairman  
[rtreagus@btchealth.com](mailto:rtreagus@btchealth.com)  
+61 417 520 509

**Forward-looking Statements**

This ASX-announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of BTC health to be materially different from the statements in this announcement.